Health Canada has approved the country’s first generic version of semaglutide, marking a significant development in the treatment of Type 2 diabetes.
The newly authorized drug, submitted by Dr. Reddy’s Laboratories, is a generic equivalent of the widely used brand-name medication Ozempic.
The approval follows a comprehensive scientific review confirming the generic product meets Canada’s standards for safety, effectiveness, and quality.
Like its brand-name counterpart, the once-weekly injection is used by adults to help manage blood sugar levels.
Health Canada says generic semaglutide products are complex synthetic drugs designed to be pharmaceutically equivalent to biologic treatments, with no meaningful differences in performance.
The introduction of generics is expected to improve accessibility, as many generic medications in Canada cost significantly less than their brand-name versions.
The agency is currently reviewing several additional submissions for generic semaglutide and expects further decisions in the coming months.
Officials say they will continue monitoring all approved versions to ensure ongoing safety and effectiveness for Canadian patients.
